Loading clinical trials...
Loading clinical trials...
A national, multicenter, randmised double blind study with parallell arms. 360 patients with grass induced allergic rhinitis will be open randomised 1:2 to 3 years Grazax sublingual immunotherapy or 3 intralymphatic injections with ALK Alutard Timothy. In a second step, the ILIT group will be double blind randomised 1:1 to an intramuscular injection of Vitamin D Vicotrat or placebo, 4 week before the start of the intralymphatic treatment. The primary outcome measure is daily combined symptoms and medication scores during grass pollen season.
Age
18 - 60 years
Sex
ALL
Healthy Volunteers
No
Skåne University Hospital, ENT department
Lund, Sweden
Örebro University Hospital
Örebro, Sweden
Karolinska University Hospital, ENT-department
Stockholm, Sweden
Start Date
February 1, 2023
Primary Completion Date
December 28, 2030
Completion Date
December 28, 2031
Last Updated
October 21, 2024
360
ESTIMATED participants
SLIT Grazax ALK Nordic 75 000 SQ-T
DRUG
ILIT + Vitamin D
DRUG
ILIT + placebo
DRUG
Lead Sponsor
Lars Olaf Cardell
NCT05191186
NCT03290248
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions